<SEC-DOCUMENT>0001193125-22-286359.txt : 20221116
<SEC-HEADER>0001193125-22-286359.hdr.sgml : 20221116
<ACCEPTANCE-DATETIME>20221116092707
ACCESSION NUMBER:		0001193125-22-286359
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221116
FILED AS OF DATE:		20221116
DATE AS OF CHANGE:		20221116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		221393364

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d395283d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;16, 2022, Kazia Therapeutics Limited (the &#147;Company&#148;) issued an ASX release titled &#147;Annual General
Meeting Results&#148; in connection with its Annual General Meeting that was held on November&nbsp;16, 2022 at 10:00 a.m. (Sydney time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein into the Company&#146;s registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST
</U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d395283dex991.htm">ASX Release of Kazia Therapeutics Limited dated November&nbsp;16, 2022 (Annual General Meeting Results) </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> (Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: November&nbsp;16, 2022</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d395283dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g395283g50g01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16&nbsp;November 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGM MATERIALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 16</B><B></B><B>&nbsp;November 2022</B> &#150; Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company,
is pleased to provide the results of the Company&#146;s AGM, held earlier today. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed phase II study in glioblastoma reported promising signals of efficacy in 2021, and a pivotal study for registration, GBM
AGILE, is ongoing, with final data expected in 2H CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in
August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U> or follow us on Twitter @KaziaTx. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annual General Meeting </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Wednesday, 16&nbsp;November 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Results of Meeting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule&nbsp;3.13.2. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Resolution details</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Instructions given to validly appointed proxies</B><br><B>(as at proxy close)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of votes cast on the poll</B><br><B>(where applicable)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Resolution</B><br><B>Result</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Resolution</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Resolution<BR>Type</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proxy&#146;s</B><br><B>Discretion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Abstain</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Abstain*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carried /</B><br><B>Not&nbsp;Carried</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">1 Adoption of Remuneration Report</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Ordinary</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">18,737,349<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61.03%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">11,787,139<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38.39%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">177,839<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">0.58%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">27,022,451</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">19,252,815<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62.03%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">11,787,139<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37.97%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">27,022,451</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Carried</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">2 <FONT STYLE="white-space:nowrap">Re-Election</FONT> of Steven Coffey</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Ordinary</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">52,294,495<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89.24%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">6,126,952<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10.46%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">178,439<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">0.30%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">2,099,020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">52,804,989<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89.60%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">6,126,952<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10.40%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">2,104,592</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Carried</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">3 Approval of grant of Options to Dr James Garner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Ordinary</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="7" NOWRAP ALIGN="center">Resolution withdrawn</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="5" NOWRAP ALIGN="center">Resolution withdrawn</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Not<BR>Applicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">4 Ratification of prior issue of ATM Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Ordinary</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">50,147,662<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83.12%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">10,002,735<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16.58%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">178,439<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">0.30%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">370,070</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">50,663,728<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83.51%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">10,002,735<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16.49%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">370,070</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Carried</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">5 Approval of Additional Placement Capacity under Listing Rule 7.1A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Special</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">50,006,395<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83.41%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">9,613,179<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16.04%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">327,938<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">0.55%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">751,394</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">50,671,960<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84.05%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">9,613,179<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15.95%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">751,394</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Carried</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">6 Adoption of New Constitution</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Special</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">52,170,337<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87.47%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">7,279,241<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12.20%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">198,439<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">0.33%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">1,050,889</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">52,700,831<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87.86%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">7,279,241<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12.14%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">1,056,461</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Carried</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">7 Approval of Proportional Takeover Provisions</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Special</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">54,531,437<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90.38%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">5,622,998<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9.32%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">178,439<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">0.30%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">366,032</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">55,041,931<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90.73%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">5,622,998<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9.27%</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">371,604</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Carried</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to resolution 1 Adoption of Remuneration Report, as more than 25% of the votes were cast against this resolution, this
constitutes a first strike for the purposes of the Corporations Act 2001 (Cth). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resolution(s) proposed but not put to the meeting </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Resolution</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Reason(s) for not putting the resolution to the
meeting</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">3 Approval of grant of Options to Dr James Garner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Resolution withdrawn prior to AGM</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g395283g50g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g395283g50g01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X QD# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=PISUXSCG)J+[5<^:TOVF;S&78S^8=Q7&,$YSC'&*.4.8V+K_DG-E_V%9_\
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MB7)13325];F1I=G->7&^&41F/#;SS@TFIR737;1W<@9XN!M&!19&\M[_ ,B
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M%*^BWD-N9I1#$3,\"Q/*!*[H0&55ZG!(%7_M^F7/BG[?<R,($17#-"2LLZJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6SH_B"
MZTN%K:*!)E=LHK9R&/';K6-3D=HY%D0X9&#*?0BJC)Q=T34A&<>62N:VIZ3J
MM@?[1N=H9Y-S-&V2C'GFC3]NK73_ -H2[RB_(A.T>_2K4NM7?B-[;2W2*!9I
M '=<G./\]*C\0>'HM)B@E@F>19&V%7 SG';%%>@JB<J?W]2L%C98><85E>_V
M>C[7Z%6+25N[^YBMY@(8CPQ^;KVJ33M.MOMES!>,K/%@*N[ /O59[;4]'VRO
M%+;"08#$<'VID^G:@+7[=/;2^2_S>:PZY[GO7,Z-9WCS:6^9WPQF#CRU%33E
M=WU]UIWLEZ>G06XNI83-9V]PS6H8A1ZCZUK6EEJ_AR$ZGY431L@$L1;D ],^
ME3+X5A.@B\^TN+CR?.!XV=,X_P#KU0O/%%Y?:9]CDCB7< ))%SEA].U=D*:I
M*[T9Y-?$SQ4K1UBG9IWT79>11U/4IM5O#<SA5. JJO10*IT45FVV[LVC%15D
M6K73;N]C:2WB#JA^8[U&/S-1"VF*PL(R1,YCC.?O," 1^HJ6SGC@AO5DSF:W
M,:8&>=P/]*N6>JQVMI8Q>7&YBG9Y#)$&*J2OW3Z\&J2BS.4IINRO_P ,4X--
MN[EY5BBR86VR9<+M/IR?8TMOIEY=AS!#O"/L;YP/F].3S5^TO[13J*S.JK<3
M!T,EOYHP"W5<]>:9INH6EG"8IHEF4W:R?-'G"@$;AZ$'!Q5*,=-27.IK9=C,
M2WFDD>-(F,B!F9<<@+U_*I+2PN;[?]FB\S9C=\P&,].M:%AJL%@]Q</YMQ<S
M2\LN%RF<G.0?O'J*9#?6EFM^L$:S+)(C0+-&2  2>1GJ,TE&/5C<ZFJ2[?\
M!*L&FWESYGE0_P"J;8^Y@NUO3D]:A%M,8UD"'8TGE*<]6]/UK3LM1@:VNUO9
M5$T\XE+26_F@\'/'8\U'8W-D+1+>ZEEC\FY\]&2/=O& ,=>#P*.6(<\TW=%>
M'2KV=IECAR86*R NHVD=>IJNT$JQ)*4.QV**?4CJ/U%7%O8VGU.612INHW"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
